| Autor: |
Pati I; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Cruciani M; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Candura F; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Massari MS; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Piccinini V; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Masiello F; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Profili S; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., De Fulvio L; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., Pupella S; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy., De Angelis V; National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy. |
| Abstrakt: |
This review is focused on the use of hyperimmune globulin therapy to treat some infectious diseases of viral or bacterial origin. Despite the introduction of antibiotics and vaccines, plasma immunoglobulin therapy from whole blood donation can still play a key role. These treatments provide passive transfer of high-titer antibodies that either reduces the risk or the severity of the infection and offer immediate but short-term protection against specific diseases. Antibody preparations derived from immunized human donors are commonly used for the prophylaxis and treatment of rabies, hepatitis A and B viruses, varicella-zoster virus, and pneumonia caused by respiratory syncytial virus, Clostridium tetani , Clostridium botulinum . The use of hyperimmune globulin therapy is a promising challenge, especially for the treatment of emerging viral infections for which there are no specific therapies or licensed vaccines. |
